Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE: GSK) to develop up to 12 innovative medicines, adding significant value to the globalization ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...